...
首页> 外文期刊>Molecular & cellular proteomics: MCP >Proteomics of Mouse BRCA1 -deficient Mammary Tumors Identifies DNA Repair Proteins with Potential Diagnostic and Prognostic Value in Human Breast Cancer
【24h】

Proteomics of Mouse BRCA1 -deficient Mammary Tumors Identifies DNA Repair Proteins with Potential Diagnostic and Prognostic Value in Human Breast Cancer

机译:小鼠BRCA1缺陷型乳腺肿瘤的蛋白质组学鉴定DNA修复蛋白在人类乳腺癌中具有潜在的诊断和预后价值

获取原文
获取原文并翻译 | 示例
           

摘要

Breast cancer 1, early onset (BRCA1) hereditary breast cancer, a type of cancer with defects in the homology-directed DNA repair pathway, would benefit from the identification of proteins for diagnosis, which might also be of potential use as screening, prognostic, or predictive markers. Sporadic breast cancers with defects in the BRCA1 pathway might also be diagnosed. We employed proteomics based on one-dimensional gel electrophore-sis in combination with nano-LC-MS/MS and spectral counting to compare the protein profiles of mammary tumor tissues of genetic mouse models either deficient or proficient in BRCA1. We identified a total of 3,545 proteins, of which 801 were significantly differentially regulated between the BRCA1 -deficient and -proficient breast tumors. Pathway and protein complex analysis identified DNA repair and related functions as the major processes associated with the up-regulated proteins in the BRCA1-deficient tumors. In addition, by selecting highly connected nodes, we identified a BRCA1 deficiency signature of 45 proteins that enriches for homology-directed DNA repair deficiency in human gene expression breast cancer data sets. This signature also exhibits prognostic power across multiple data sets, with optimal performance in a data set enriched in tumors deficient in homology-directed DNA repair. In conclusion, by comparing mouse proteomes from BRCA1-proficient and -deficient mammary tumors, we were able to identify several markers associated with BRCA1 deficiency and a prognostic signature for human breast cancer deficient in homology-directed DNA repair.
机译:乳腺癌1,早发性(BRCA1)遗传性乳腺癌是一种在同源性导向的DNA修复途径中存在缺陷的癌症,它将受益于蛋白质的鉴定以进行诊断,也可能在筛查,预后,或预测标记。 BRCA1途径缺陷的散发性乳腺癌也可能被诊断出来。我们采用基于一维凝胶电泳结合纳米LC-MS / MS和光谱计数的蛋白质组学来比较BRCA1缺陷或熟练的遗传小鼠模型乳腺肿瘤组织的蛋白质谱。我们鉴定出总共3,545种蛋白质,其中801种在BRCA1缺陷和熟练的乳腺肿瘤之间有明显的差异调节。途径和蛋白质复合物分析确定DNA修复和相关功能是与BRCA1缺陷型肿瘤中蛋白质上调相关的主要过程。此外,通过选择高度连接的节点,我们鉴定了45种蛋白质的BRCA1缺乏症特征,该特征丰富了人类基因表达乳腺癌数据集中同源性指导的DNA修复缺陷。该签名还显示了跨多个数据集的预后能力,在充斥缺乏同源性指导的DNA修复的肿瘤的数据集中具有最佳性能。总之,通过比较来自BRCA1熟练和缺陷乳腺肿瘤的小鼠蛋白质组,我们能够鉴定出与BRCA1缺乏相关的几种标记物,以及缺乏针对同源性指导的DNA修复的人类乳腺癌的预后标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号